The holdings that drove the model's growth. Strategies The stocks that delivered for the Concentrated GARP model
My largest holding is down 40% but I bought more. Strategies Why I’m sticking with GT Advanced Technologies
We like the Aberdeen Chile Fund's reliable dividend. Strategies We’re doubling down on the Aberdeen Chile Fund
Manager Mike Arold is watching one signal, in particular, for cues. Outlook Strategies When the post-election market blues might ease
The case for high yielding stocks - even if the dividend tax goes way up. Outlook Strategies Dividend stocks in this time of tax policy uncertainty
On any given day, the noise of the market is far more powerful than any signal. Strategies The market is an over-reaction machine
Unleash your inner Spock: If you love a stock, it will not love you back. Strategies Investors, curb your enthusiasm
Here's why I believe the generic drug leader is now an undervalued stock. Strategies Teva Pharmaceutical is an attractive buying opportunity
Here are the core questions I ask when valuing biotech stocks. Strategies Simple trumps complex for biotech stock investing
A breakout or breakdown of small-cap stocks may be very telling. Outlook Strategies This chart may soon give us important market cues
Stocks are hanging in there, despite a deluge of bad news. Outlook Strategies Like the East Coast, the U.S. market remains resilient
